Please select the eligibility criteria that correspond to the clinical trial below.
Title: Amblyopia Treatment Study: Occlusion Versus Pharmacologic Therapy for Moderate Amblyopia
Brief Summary: * To determine whether the success rate with drug treatment (atropine) of amblyopia due to strabismus or anisometropia in patients less than 7 years old is equivalent to the success rate with occlusion (patching) therapy
* To develop more precise estimates of the success rates of amblyopia treatment
* To identify factors that may be associated with successful treatment of amblyopia
* To collect data on the course of treated amblyopia to provide more precise estimates of treatment effects than are now available

Extended Follow up of Study Patients

* Primary: To determine the long-term visual acuity outcome at age 10 years and at age 15 years in patients diagnosed with amblyopia before age 7 years.
* Secondary: To determine whether the long-term visual acuity outcome at age 10 years and at age 15 years differs between patients who received patching followed by best clinical care and patients who received atropine followed by best clinical care


Options:
A: Inclusion Criteria:

* Age 3 to \< 10 years
* Amblyopia associated with strabismus, anisometropia, or both
* Visual acuity in the amblyopic eye between 20/32 and 20/63 inclusive
* Visual acuity in the sound eye 20/32 or better and inter-eye acuity difference \>= 2 logMAR lines
* Current/previous treatment with patching and/or atropine subject to the following stipulations:

  * No simultaneous treatment with patching and atropine in the past 6 months
  * No prior use of atropine in combination with the sound eye spectacle lens reduced by more than 1.50 D
  * Maximum level of any previous treatment:

    * Patching: up to 42 hours per week (averaging 6 hours daily)
    * Atropine: up to once daily
  * Current treatment with 42 hours per week patching or daily atropine
* No improvement in best-corrected amblyopic eye visual acuity between two consecutive visits at least 6 weeks apart using the same testing method and optimal spectacle correction (if needed), with no improvement defined as follows:

  * No lines of improvement
  * For patients tested using E-ETDRS, letter score that is no more than 4 letters improved
* Wearing spectacles with optimal correction (if applicable)
* Investigator ready to wean or stop treatment

Exclusion Criteria:

* Current vision therapy or orthoptics
* Ocular cause for reduced visual acuity
* Prior intraocular or refractive surgery
* Strabismus surgery planned within 10 weeks
* Known allergy to atropine or other cycloplegic drugs
* Known skin reactions to patch or bandage adhesives
* Down Syndrome present
B: Inclusion Criteria:

* Patients must be 7 years old or younger with amblyopia due to strabismus or anisometropia
* Visual acuity in the amblyopic eye must be between 20/40 and 20/100
* Visual acuity in the sound eye or 20/40 or better
* At least 3 lines of acuity difference between the two eyes

Exclusion Criteria:

* More than two months of amblyopia therapy in the past two years
* Myopia (more than -0.50 D)
C: Inclusion Criteria:

* Patients must be aged 7 to \<18 years and have amblyopia associated with strabismus, anisometropia, or both.
* Visual acuity in the amblyopic eye must be 20/40 to 20/400 inclusive and visual acuity in the sound eye must be 20/25 or better.

Exclusion Criteria:

* Patients must not have received amblyopia treatment (other than spectacles) in the past month or more than one month of amblyopia treatment in the last 6 months.
D: Inclusion Criteria:

* Age 7 to 12 years old (inclusive)
* Amblyopia associated with strabismus, anisometropia, or both
* Visual acuity in the amblyopic eye 19 to 71 letters on Electronic Early Treatment Diabetic Retinopathy Study (E-ETDRS©) (20/40 to 20/400 inclusive)
* Visual acuity in the sound eye 79 letters or better on E-ETDRS© (20/25 or better)
* Interocular difference \>=15 letters (3 lines)
* Spectacles, if needed, worn for at least 16 weeks or visual acuity documented to be stable

Inclusion Criteria for Optional Ancillary Study:

* Enrolled into the main study
* Refractive error in both eyes between -0.25 and +5.00D, inclusive (to avoid the need to adjust for refractive error)
* Birth weight \>1500 grams
* No history of Central Nervous System (CNS) disease (e.g. intraventricular hemorrhage (IVH), periventricular leukomalacia (PVL), meningitis, developmental abnormalities of the brain, hydrocephalus, cerebral palsy, hypoxic ischemic encephalopathy

Exclusion Criteria:

* Amblyopia treatment (other than spectacles) in the last 6 months
* Myopia (more than -0.25D spherical equivalent) in either eye

Answer: B